{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T17:13:27Z","timestamp":1788369207696,"version":"build-2803163510"},"reference-count":57,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,11,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunotherapy using bispecific antibodies including bispecific T-cell engager (BiTE) has the potential to enhance the efficacy of treatment for relapsed\/refractory multiple myeloma. However, myeloma may still recur after treatment because of downregulation of a target antigen and\/or myeloma cell heterogeneity. To strengthen immunotherapy for myeloma while overcoming its characteristics, we have newly developed a BiTE-based modality, referred to as bridging-BiTE (B-BiTE). B-BiTE was able to bind to both a human immunoglobulin G\u2013Fc domain and the CD3 molecule. Clinically available monoclonal antibodies (mAbs) were bound with B-BiTE before administration, and the mAb\/B-BiTE complex induced antitumor T-cell responses successfully while preserving and supporting natural killer cell reactivity, resulting in enhanced antimyeloma effects via dual-lymphoid activation. In contrast, any unwanted off-target immune-cell reactivity mediated by mAb\/B-BiTE complexes or B-BiTE itself appeared not to be observed in\u00a0vitro and in\u00a0vivo. Importantly, sequential immunotherapy using 2 different mAb\/B-BiTE complexes appeared to circumvent myeloma cell antigen escape, and further augmented immune responses to myeloma relative to those induced by mAb\/B-BiTE monotherapy or sequential therapy with 2 mAbs in the absence of B-BiTE. Therefore, this modality facilitates easy and prompt generation of a broad panel of bispecific antibodies that can induce deep and durable antitumor responses in the presence of clinically available mAbs, supporting further advancement of reinforced immunotherapy for multiple myeloma and other refractory hematologic malignancies.<\/jats:p>","DOI":"10.1182\/blood.2022019082","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T20:55:05Z","timestamp":1695416105000},"page":"1789-1805","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Reinforced antimyeloma therapy via dual-lymphoid activation mediated by a panel of antibodies armed with bridging-BiTE"],"prefix":"10.1182","volume":"142","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6203-9435","authenticated-orcid":false,"given":"Tatsuya","family":"Konishi","sequence":"first","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8440-6144","authenticated-orcid":false,"given":"Toshiki","family":"Ochi","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"},{"name":"2Division of Immune Regulation, Proteo-Science Center, Ehime University, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Maruta","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushi","family":"Tanimoto","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukihiro","family":"Miyazaki","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7139-325X","authenticated-orcid":false,"given":"Chika","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0532-8112","authenticated-orcid":false,"given":"Takashi","family":"Saitou","sequence":"additional","affiliation":[{"name":"3Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5101-4304","authenticated-orcid":false,"given":"Takeshi","family":"Imamura","sequence":"additional","affiliation":[{"name":"3Department of Molecular Medicine for Pathogenesis, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaki","family":"Yasukawa","sequence":"additional","affiliation":[{"name":"2Division of Immune Regulation, Proteo-Science Center, Ehime University, Toon, Ehime, Japan"},{"name":"4Ehime Prefectural University of Health Sciences, Tobe, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuto","family":"Takenaka","sequence":"additional","affiliation":[{"name":"1Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Ehime, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"22","key":"2023112316205752400_bib1","doi-asserted-by":"crossref","first-page":"5419","DOI":"10.1158\/1078-0432.CCR-16-0625","article-title":"Progress and paradigms in multiple myeloma","volume":"22","author":"Anderson","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023112316205752400_bib2","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"issue":"9","key":"2023112316205752400_bib3","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"issue":"3","key":"2023112316205752400_bib4","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1038\/s41375-021-01453-5","article-title":"Mortality trends in multiple myeloma after the introduction of novel therapies in the United States","volume":"36","author":"Binder","year":"2022","journal-title":"Leukemia"},{"key":"2023112316205752400_bib5","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/ncomms3997","article-title":"Heterogeneity of genomic evolution and mutational profiles in multiple myeloma","volume":"5","author":"Bolli","year":"2014","journal-title":"Nat Commun"},{"issue":"1","key":"2023112316205752400_bib6","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41467-017-00296-y","article-title":"Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing","volume":"8","author":"Rasche","year":"2017","journal-title":"Nat Commun"},{"issue":"12","key":"2023112316205752400_bib7","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1038\/s41591-018-0269-2","article-title":"Single cell dissection of plasma cell heterogeneity in symptomatic and asymptomatic myeloma","volume":"24","author":"Ledergor","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2023112316205752400_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/bjh.15210","article-title":"Resistance to proteasome inhibitors and other targeted therapies in myeloma","volume":"182","author":"Wallington-Beddoe","year":"2018","journal-title":"Br J Haematol"},{"issue":"7","key":"2023112316205752400_bib9","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"24","key":"2023112316205752400_bib10","doi-asserted-by":"crossref","first-page":"7498","DOI":"10.1158\/1078-0432.CCR-17-2027","article-title":"Monocytes and granulocytes reduce CD38 expression levels on myeloma cells in patients treated with daratumumab","volume":"23","author":"Krejcik","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2023112316205752400_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1182\/blood-2012-01-405985","article-title":"Clonal competition with alternating dominance in multiple myeloma","volume":"120","author":"Keats","year":"2012","journal-title":"Blood"},{"issue":"8","key":"2023112316205752400_bib12","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"10297","key":"2023112316205752400_bib13","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen\u00a0receptor T-cell therapy in patients with relapsed or refractory multiple myeloma\u00a0(CARTITUDE-1): a phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"issue":"13","key":"2023112316205752400_bib14","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"2023112316205752400_bib15","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1200\/JCO.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2023112316205752400_bib16","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1158\/2643-3230.BCD-21-0028","article-title":"Bispecific antibodies in multiple myeloma: present and future","volume":"2","author":"Lancman","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"10301","key":"2023112316205752400_bib17","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"2023112316205752400_bib18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2023112316205752400_bib19","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1182\/bloodadvances.2020001792","article-title":"BiTEs better than CAR T cells","volume":"5","author":"Subklewe","year":"2021","journal-title":"Blood Adv"},{"key":"2023112316205752400_bib20","doi-asserted-by":"crossref","first-page":"762","DOI":"10.3389\/fimmu.2020.00762","article-title":"Bispecific, T-cell-recruiting antibodies in B-cell malignancies","volume":"11","author":"Lejeune","year":"2020","journal-title":"Front Immunol"},{"issue":"20","key":"2023112316205752400_bib21","doi-asserted-by":"crossref","first-page":"5457","DOI":"10.1158\/1078-0432.CCR-20-3770","article-title":"Bispecific immunomodulatory antibodies for cancer immunotherapy","volume":"27","author":"Blanco","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2023112316205752400_bib22","doi-asserted-by":"crossref","first-page":"13293","DOI":"10.1038\/s41598-019-49834-2","article-title":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy","volume":"9","author":"Maruta","year":"2019","journal-title":"Sci Rep"},{"issue":"1","key":"2023112316205752400_bib23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/s42003-021-01791-1","article-title":"A\u00a0single-chain antibody generation system yielding CAR-T cells with superior antitumor function","volume":"4","author":"Ochi","year":"2021","journal-title":"Commun Biol"},{"key":"2023112316205752400_bib24","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.3389\/fimmu.2020.01635","article-title":"Considerations of antibody geometric constraints on NK cell antibody dependent cellular cytotoxicity","volume":"11","author":"Murin","year":"2020","journal-title":"Front Immunol"},{"issue":"1","key":"2023112316205752400_bib25","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1186\/s13045-021-01216-w","article-title":"Bispecific antibody-activated T cells enhance NK cell-mediated antibody-dependent cellular cytotoxicity","volume":"14","author":"Wang","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"3","key":"2023112316205752400_bib26","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1681\/ASN.V103519","article-title":"Nodular glomerulosclerosis with deposition of monoclonal immunoglobulin heavy chains lacking C(H)1","volume":"10","author":"Moulin","year":"1999","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9","key":"2023112316205752400_bib27","doi-asserted-by":"crossref","first-page":"6591","DOI":"10.1074\/jbc.M009483200","article-title":"High resolution mapping of the binding site on human IgG1 for Fc gamma RI, Fc gamma RII, Fc gamma RIII, and FcRn and design of IgG1 variants with improved binding to the Fc gamma R","volume":"276","author":"Shields","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"2023112316205752400_bib28","doi-asserted-by":"crossref","first-page":"740","DOI":"10.3389\/fimmu.2020.00740","article-title":"Fc\u03b3R binding and ADCC activity of human IgG allotypes","volume":"11","author":"de Taeye","year":"2020","journal-title":"Front Immunol"},{"issue":"3","key":"2023112316205752400_bib29","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.4049\/jimmunol.163.3.1246","article-title":"Simultaneous activation of T cells and accessory cells by a new class of intact bispecific antibody results in efficient tumor cell killing","volume":"163","author":"Zeidler","year":"1999","journal-title":"J\u00a0Immunol"},{"issue":"15","key":"2023112316205752400_bib30","doi-asserted-by":"crossref","first-page":"4663","DOI":"10.1158\/0008-5472.CAN-12-4460","article-title":"Potent immunomodulatory effects of the trifunctional antibody catumaxomab","volume":"73","author":"Goere","year":"2013","journal-title":"Cancer Res"},{"issue":"19","key":"2023112316205752400_bib31","doi-asserted-by":"crossref","first-page":"28059","DOI":"10.18632\/oncotarget.8574","article-title":"Immune-mediated liver injury of the cancer therapeutic antibody catumaxomab targeting EpCAM, CD3 and Fc\u03b3 receptors","volume":"7","author":"Borlak","year":"2016","journal-title":"Oncotarget"},{"issue":"10","key":"2023112316205752400_bib32","doi-asserted-by":"crossref","first-page":"2301","DOI":"10.1007\/s00262-022-03163-y","article-title":"Engineering T-cells with chimeric antigen receptors to combat hematological cancers: an update on clinical trials","volume":"71","author":"Ormhoj","year":"2022","journal-title":"Cancer Immunol Immunother"},{"issue":"26","key":"2023112316205752400_bib33","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1182\/blood-2017-04-778423","article-title":"SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7(+) normal lymphocytes","volume":"130","author":"Gogishvili","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2023112316205752400_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1182\/blood-2017-06-740944","article-title":"CD38 antibodies in multiple myeloma: back to the future","volume":"131","author":"van de Donk","year":"2018","journal-title":"Blood"},{"issue":"1","key":"2023112316205752400_bib35","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1186\/s13045-021-01170-7","article-title":"A\u00a0bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma","volume":"14","author":"Mei","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023112316205752400_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-021-01092-4","article-title":"CD38-directed CAR-T cell therapy: a novel immunotherapy strategy for relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation","volume":"14","author":"Cui","year":"2021","journal-title":"J\u00a0Hematol Oncol"},{"issue":"4","key":"2023112316205752400_bib37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1158\/2643-3230.BCD-20-0227","article-title":"Determinants of response and mechanisms of resistance of CAR T-cell therapy in multiple myeloma","volume":"2","author":"van de Donk","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"4","key":"2023112316205752400_bib38","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"issue":"1","key":"2023112316205752400_bib39","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13045-020-01001-1","article-title":"Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma","volume":"13","author":"Roex","year":"2020","journal-title":"J\u00a0Hematol Oncol"},{"issue":"1","key":"2023112316205752400_bib40","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1080\/07853890.2021.1970218","article-title":"Comprehensive meta-analysis of anti-BCMA chimeric antigen receptor T-cell therapy in relapsed or refractory multiple myeloma","volume":"53","author":"Zhang","year":"2021","journal-title":"Ann Med"},{"issue":"8","key":"2023112316205752400_bib41","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.3324\/haematol.2020.276402","article-title":"European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma","volume":"106","author":"Bruno","year":"2021","journal-title":"Haematologica"},{"issue":"10","key":"2023112316205752400_bib42","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1080\/03007995.2021.1953456","article-title":"Matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myeloma","volume":"37","author":"Martin","year":"2021","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"2023112316205752400_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13046-021-02214-z","article-title":"High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma","volume":"41","author":"Tang","year":"2022","journal-title":"J\u00a0Exp Clin Cancer Res"},{"issue":"1","key":"2023112316205752400_bib44","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1038\/s41467-020-16160-5","article-title":"Systematically optimized BCMA\/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma","volume":"11","author":"Zah","year":"2020","journal-title":"Nat Commun"},{"issue":"2","key":"2023112316205752400_bib45","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1158\/2643-3230.BCD-20-0020","article-title":"Defining an optimal dual-targeted CAR T-cell therapy approach simultaneously targeting BCMA and GPRC5D to prevent BCMA escape-driven relapse in multiple myeloma","volume":"1","author":"Fern\u00e1ndez de Larrea","year":"2020","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2023112316205752400_bib46","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1038\/s41467-021-21177-5","article-title":"Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma","volume":"12","author":"Samur","year":"2021","journal-title":"Nat Commun"},{"issue":"7","key":"2023112316205752400_bib47","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1177\/1060028016642786","article-title":"Immunotherapy: a new approach to treating multiple myeloma with daratumumab and elotuzumab","volume":"50","author":"Afifi","year":"2016","journal-title":"Ann Pharmacother"},{"issue":"78","key":"2023112316205752400_bib48","doi-asserted-by":"crossref","first-page":"34784","DOI":"10.18632\/oncotarget.26196","article-title":"Clinical impact of serum soluble SLAMF7 in multiple myeloma","volume":"9","author":"Ishibashi","year":"2018","journal-title":"Oncotarget"},{"issue":"4","key":"2023112316205752400_bib49","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1158\/2643-3230.BCD-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"1","key":"2023112316205752400_bib50","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/1078-0432.CCR-17-0344","article-title":"Lenalidomide enhances the function of CS1 chimeric antigen receptor-redirected T cells against multiple myeloma","volume":"24","author":"Wang","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"12","key":"2023112316205752400_bib51","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1158\/1535-7163.MCT-18-1146","article-title":"Anti-B-cell maturation antigen chimeric antigen receptor T cell function against multiple myeloma is enhanced in the presence of lenalidomide","volume":"18","author":"Works","year":"2019","journal-title":"Mol Cancer Ther"},{"issue":"17","key":"2023112316205752400_bib52","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1182\/bloodadvances.2020002524","article-title":"The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models","volume":"4","author":"Cho","year":"2020","journal-title":"Blood Adv"},{"issue":"1","key":"2023112316205752400_bib53","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41375-020-0840-y","article-title":"Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab","volume":"35","author":"Garcia-Guerrero","year":"2021","journal-title":"Leukemia"},{"issue":"6","key":"2023112316205752400_bib54","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2023112316205752400_bib55","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1089\/hyb.1984.3.263","article-title":"Evaluation of thirty-one mouse monoclonal antibodies to human IgG epitopes","volume":"3","author":"Reimer","year":"1984","journal-title":"Hybridoma"},{"issue":"3-4","key":"2023112316205752400_bib56","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/0165-2478(85)90082-3","article-title":"Evaluation of monoclonal antibodies having specificity for human IgG sub-classes: results of an IUIS\/WHO collaborative study","volume":"10","author":"Jefferis","year":"1985","journal-title":"Immunol Lett"},{"issue":"4","key":"2023112316205752400_bib57","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat Rev Immunol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/21\/1789\/2090041\/blood_bld-2022-019082-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/142\/21\/1789\/2090041\/blood_bld-2022-019082-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,23]],"date-time":"2023-11-23T16:22:57Z","timestamp":1700756577000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/142\/21\/1789\/498042\/Reinforced-antimyeloma-therapy-via-dual-lymphoid"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,23]]},"references-count":57,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2023,11,23]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2022019082","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,23]]}}}